Table 1 Demographic, clinical, and metabolic characteristics of TR and NTR groups in the multi-omics cohort
Variables | TR (n = 95) | NTR (n = 113) | χ2 / U | P |
|---|---|---|---|---|
Age (years) | 33.81 ± 10.61 | 32.98 ± 10.03 | 5560 | 0.657 |
Sex (male) | 36 (37.89%) | 51 (45.13%) | 1.111 | 0.292 |
Educational level | - | 0.266 | ||
College and above | 34 (35.79%) | 29 (25.66%) | ||
High school | 37 (38.95%) | 52 (46.02%) | ||
Middle school | 19 (20.00%) | 29 (25.66%) | ||
Primary school and below | 5 (5.26%) | 3 (2.66%) | ||
First episode (yes) | 29 (30.53%) | 28 (24.78%) | 0.857 | 0.355 |
Family history of mental illness (yes) | 18 (18.95%) | 27 (23.89%) | 0.745 | 0.388 |
Smoking history (yes) | 10 (10.53%) | 18 (15.93%) | 1.293 | 0.255 |
Drinking history (yes) | 7 (7.37%) | 10 (8.85%) | 0.151 | 0.698 |
Disease duration (years) | 7.28 ± 6.86 | 8.09 ± 7.01 | 4893 | 0.272 |
PANSS at baseline | 83.66 ± 17.18 | 78.40 ± 11.53 | 6178 | 0.061 |
Antipsychotics discontinued at baseline | 5.448 | 0.066 | ||
Second-generation antipsychotics | 10 (10.53%) | 16 (14.16%) | ||
First-generation antipsychotics | 4 (4.21%) | 14 (12.39%) | ||
No regular antipsychotics use | 81 (85.26%) | 83 (73.45%) | ||
Mood stabilizers use | 3 (3.16%) | 4 (3.54%) | - | 1 |
Antidepressants use | 3 (3.16%) | 2 (1.77%) | - | 0.662 |
Benzodiazepines use | 31 (32.63%) | 38 (33.63%) | 0.023 | 0.879 |
Metabolic profile at baseline | ||||
BMI | 23.17 ± 4.71 | 23.91 ± 4.53 | 5970 | 0.164 |
Triglyceride (mmol/L) | 1.20 ± 0.67 | 1.29 ± 0.77 | 5780 | 0.341 |
Cholesterol (mmol/L) | 4.64 ± 1.65 | 4.48 ± 0.99 | 5160 | 0.632 |
LDL cholesterol (mmol/L) | 2.68 ± 0.73 | 2.68 ± 0.79 | 5330 | 0.931 |
HDL cholesterol (mmol/L) | 1.27 ± 0.36 | 1.21 ± 0.33 | 4844 | 0.226 |
Fasting blood glucose (mmol/L) | 5.01 ± 0.96 | 4.99 ± 1.01 | 5100 | 0.537 |
